A novel dendritic nanocarrier of polyamidoamine-polyethylene glycol-cyclic RGD for "smart" small interfering RNA delivery and in vitro antitumor effects by human ether-à-go-go-related gene silencing in anaplastic thyroid carcinoma cells

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1293-1306

  Li, Guanhua ^a   Hu, Zuojun ^a   Yin, Henghui ^a   Zhang, Yunjian ^a   Huang, Xueling ^a   Wang, Shenming ^a   Li, Wen ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Anaplastic thyroid cancer; Dendrimer; Gene silencing; Human ether go go related gene; Small interfering RNA

Indexed keywords

CASPASE 3; CYCLIC ARGINYLGLYCYLASPARTIC ACID; DRUG CARRIER; FLUORESCENT DYE; INTEGRIN; MACROGOL; NANOCARRIER; POLYAMIDOAMINE; POLYAMIDOAMINE MACROGOL CYCLIC ARGINYLGLYCYLASPARTIC ACID; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

AGAR GEL ELECTROPHORESIS; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ENDOCYTOSIS; ETHER A GO GO RELATED GENE; EXCIPIENT COMPATIBILITY; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; INTERNALIZATION; LIGAND BINDING; LIGHT SCATTERING; NANOANALYSIS; NANOFABRICATION; NANOPHARMACEUTICS; ONCOGENE; PARTICLE SIZE; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA BINDING; RNA VECTOR; STATIC ELECTRICITY; THYROID CARCINOMA; WESTERN BLOTTING; ZETA POTENTIAL;

ANAPLASTIC THYROID CANCER; DENDRIMER; GENE SILENCING; HUMAN ETHER-À-GO-GO-RELATED GENE; SMALL INTERFERING RNA;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MEMBRANE; CELL SURVIVAL; DENDRIMERS; DRUG CARRIERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ETHER-A-GO-GO POTASSIUM CHANNELS; GENE SILENCING; HUMANS; LIGHT; NANOPARTICLES; PARTICLE SIZE; PEPTIDES, CYCLIC; POLYETHYLENE GLYCOLS; RNA, SMALL INTERFERING; SCATTERING, RADIATION; THYROID NEOPLASMS; TRANSFECTION;

EID: 84875661289     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S41555     Document Type: Article

References (62)

1. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007;59(2-3):75-86.
2. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J. 2011;6(9):1130-1146.
3. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129-138.
4. Kukowska-Latallo JF, Bielinska AU, Johnson J, Spindler R, Tomalia DA, Baker JR Jr. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc Natl Acad Sci U S A. 1996;93(10):4897-4902.
5. Liu XX, Rocchi P, Qu FQ, etal. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells. Chem Med Chem. 2009;4(8):1302-1310.
6. Kim ID, Shin JH, Kim SW, etal. Intranasal delivery of HMGB1siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol Ther. 2012;20(4):829-839.
7. Zhou J, Neff CP, Liu X, etal. Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppressesHIV-1infection in humanized mice. Mol Ther. 2011;19(12):2228-2238.
8. Arima H, Tsutsumi T, Yoshimatsu A, etal. Inhibitory effect of siRNA complexes with polyamidoamine dendrimer/α-cyclodextrin conjugate (generation 3, G3) on endogenous gene expression. Eur J Pharm Sci. 2011;44(3):375-384.
9. Neff RL, Farrar WB, Kloos RT, Burman KD. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am. 2008;37(2):525-538.
10. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440(7083):463-469.
11. Wadhwa S, Wadhwa P, Dinda AK, Gupta NP. Differential expression of potassium ion channels in human renal cell carcinoma. Int Urol Nephrol. 2009;41(2):251-257.
12. Masi A, Becchetti A, Restano-Cassulini R, et al. hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br J Cancer. 2005;93(7):781-792.
13. Pillozzi S, Brizzi MF, Balzi M, et al. hERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia. 2002;16(9):1791-1798.
14. Wang Y, Zhang Y, Yang L, etal. Arsenic trioxide induces the apoptosis of human breast cancer MCF-7cells through activation of caspase-3 and inhibition of hERG channels. Exp Ther Med. 2011;2(3):481-486.
15. Pardo LA, Contreras-Jurado C, Zientkowska M, Alves F, Stühmer W. Role of voltage-gated potassium channels in cancer. J Membr Biol. 2005;205(3):115-124.
16. Rust WL, Carper SW, Plopper GE. The promise of integrins as effective targets for anticancer agents. J Biomed Biotechnol. 2002;2(3):124-130.
17. Cai W, Chen X. Anti-angiogenic cancer therapy based on integrin alphaVbeta3 antagonism. Anticancer Agents Med Chem. 2006;6(5): 407-428.
18. Aumailley M, Gurrath M, Müller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides: Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. 1991;291(1):50-54.
19. Nabors LB, Mikkelsen T, Rosenfeld SS, etal. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007;25(13):1651-1657.
20. Reardon DA, Fink KL, Mikkelsen T, etal. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008;26(34):5610-5617.
21. Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R. Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol. 2011;7(3):339-354.
22. Lee MH, Kim JY, Han JH, etal. Direct fluorescence monitoring of the delivery and cellular uptake of a cancer-targeted RGD peptide-appended naphthalimide theragnostic prodrug. J Am Chem Soc. 2012;134(30):12668-12674.
23. Danhier F, Pourcelle V, Marchand-Brynaert J, Jérôme C, Feron O, Préat V. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles. Methods Enzymol. 2012;508:157-175.
24. Boswell CA, Eck PK, Regino CA, etal. Synthesis, characterization, and biological evaluation of integrin alphaVbeta3-targeted PAMAM dendrimers. Mol Pharm. 2008;5(4):527-539.
25. Wang YY, Lü LX, Shi JC, Wang HF, Xiao ZD, Huang NP. Introducing RGD peptides on PHBV films through PEG-containing cross-linkers to improve the biocompatibility. Biomacromolecules. 2011;12(3):551-559.
26. Natarajan A, Xiong CY, Albrecht H, DeNardo GL, DeNardo SJ. Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals. Bioconjug Chem. 2005;16(1):113-121.
27. Pedraza CE, Bassett DC, McKee MD, Nelea V, Gbureck U, Barralet JE. The importance of particle size and DNA condensation salt for calcium phosphate nanoparticle transfection. Biomaterials. 2008;29(23): 3384-3392.
28. Patil Y, Panyam J. Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm. 2009;367(1-2):195-203.
29. Wagner E, Cotten M, Foisner R, Birnstiel ML. Transferrin-polycation-DNA complexes: the effect of polycations on the structure of the complex and DNA delivery to cells. Proc Natl Acad Sci U S A. 1991;88(10):4255-4259.
30. Agashe HB, Dutta TD, Garg M, Jain NK. Investigations on the toxicological profile of functionalized fifth-generation poly(propyleneimine) dendrimer. J Pharm Pharmacol. 2006;58(11):1491-1498.
31. Wang YX, Robertson JL, Spillman WB Jr, Claus RO. Effects of the chemical structure and the surface properties of polymeric biomaterials on their biocompatibility. Pharm Res. 2004;21(8):1362-1373.
32. Wang W, Xiong W, Wan J, Sun X, Xu H, Yang X. The decrease of PAMAM dendrimer-induced cytotoxicity by PEGylation via attenuation of oxidative stress. Nanotechnology. 2009;20(10):105103.
33. Gajbhiye V, Vijayaraj Kumar P, Kumar Tekade R, Jain NK. Pharmaceutical and biomedical potential of PEGylated dendrimers. Curr Pharm Des. 2007;13(4):415-429.
34. Fiandalo MV, Kyprianou N. Caspase control: protagonists of cancer cell apoptosis. Exp Oncol. 2012;34(3):165-175.
35. Raviña M, Paolicelli P, Seijo B, Sanchez A. Knocking down gene expression with dendritic vectors. Mini Rev Med Chem. 2010;10(1): 73-86.
36. Deshpande MC, Davies MC, Garnett MC, etal. The effect of poly(ethylene glycol) molecular architecture on cellular interaction and uptake of DNA complexes. J Control Release. 2004;97(1):143-156.
37. Li SD, Chono S, Huang L. Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release. 2008;126(1):77-84.
38. Li W, Huang Z, MacKay JA, Grube S, Szoka FC Jr. Low-pH-sensitive poly(ethylene glycol) (PEG)-stabilized plasmid nanolipoparticles: effects of PEG chain length, lipid composition and assembly conditions on gene delivery. J Gene Med. 2005;7(1):67-79.
39. Patil ML, Zhang M, Minko T. Multifunctional triblock nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing. ACS Nano. 2011;5(3):1877-1887.
40. Chandna P, Saad M, Wang Y, etal. Targeted proapoptotic anticancer drug delivery system. Mol Pharm. 2007;4(5):668-678.
41. Patil ML, Zhang M, Taratula O, Garbuzenko OB, He H, Minko T. Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting. Biomacromolecules. 2009;10(2):258-266.
42. Inoue Y, Kurihara R, Tsuchida A, etal. Efficient delivery of siRNA using dendritic poly(L-lysine) for loss-of-function analysis. J Control Release. 2008;126(1):59-66.
43. Kano A, Moriyama K, Yamano T, Nakamura I, Shimada N, Maruyama A. Grafting of poly(ethylene glycol) to poly-lysine augments its lifetime in blood circulation and accumulation in tumors without loss of the ability to associate with siRNA. J Control Release. 2011;149(1):2-7.
44. Karatasos K, Posocco P, Laurini E, Pricl S. Poly(amidoamine)-based dendrimer/siRNA complexation studied by computer simulations: effects of pH and generation on dendrimer structure and siRNA binding. Macromol Biosci. 2012;12(2):225-240.
45. Ouyang D, Zhang H, Parekh HS, Smith SC. The effect of pH on PAMAM dendrimer-siRNA complexation: endosomal considerations as determined by molecular dynamics simulation. Biophys Chem. 2011;158(2-3):126-133.
46. Jensen LB, Pavan GM, Kasimova MR, etal. Elucidating the molecular mechanism of PAMAM-siRNA dendriplex self-assembly: effect of dendrimer charge density. Int J Pharm. 2011;416(2):410-418.
47. Dahlman T, Grimelius L, Wallin G, Rubin K, Westermark K. Integrins in thyroid tissue: upregulation of alpha2beta1in anaplastic thyroid carcinoma. Eur J Endocrinol. 1998;138(1):104-112.
48. Waite CL, Roth CM. PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma. Bioconjug Chem. 2009;20(10):1908-1916.
49. Huang TC, Huang HC, Chang CC, etal. An apoptosis-related gene network induced by novel compound-cRGD in human breast cancer cells. FEBS Lett. 2007;581(18):3517-3522.
50. Yang W, Meng L, Wang H, etal. Inhibition of proliferative and invasive capacities of breast cancer cells by arginine-glycine-aspartic acid peptide in vitro. Oncol Rep. 2006;15(1):113-117.
51. Albertazzi L, Gherardini L, Brondi M, etal. In vivo distribution and toxicity of PAMAM dendrimers in the central nervous system depend on their surface chemistry. Mol Pharm. 2013;10(1):249-260.
52. Roberts JC, Bhalgat MK, Zera RT. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J Biomed Mater Res. 1996;30(1):53-65.
53. Sadekar S, Ghandehari H. Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery. Adv Drug Deliv Rev. 2012;64(6):571-588.
54. Bianchi L, Wible B, Arcangeli A, etal. hERG encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells? Cancer Res. 1998;58(4):815-822.
55. Shao XD, Wu KC, Guo XZ, Xie MJ, Zhang J, Fan DM. Expression and significance of hERG protein in gastric cancer. Cancer Biol Ther. 2008;7(1):45-50.
56. Ishihara K, Hiraoka M. Gating mechanism of the cloned inward rectifier potassium channel from mouse heart. J Membr Biol. 1994;142(1): 55-64.
57. Wonderlin WF, Strobl JS. Potassium channels, proliferation and G1 progression. J Membr Biol. 1996;154(2):91-107.
58. Lin H, Xiao J, Luo X, etal. Overexpression hERG K(+) channel gene mediates cell-growth signals on activation of oncoproteins SP1 and NF-kappaB and inactivation of tumor suppressor Nkx3.1. J Cell Physiol. 2007;212(1):137-147.
59. Jehle J, Schweizer PA, Katus HA, Thomas D. Novel roles for hERG K(+) channels in cell proliferation and apoptosis. Cell Death Dis. 2011;2:e193.
60. Eiras S, Fernández P, Piñeiro R, Iglesias MJ, González-Juanatey JR, Lago F. Doxazosin induces activation of GADD153 and cleavage of focal adhesion kinase in cardiomyocytes route to apoptosis. Cardiovasc Res. 2006;71(1):118-128.
61. Cherubini A, Hofmann G, Pillozzi S, etal. Human ether-a-go go-related gene 1 channels are physically linked to beta1integrins and modulate adhesion dependent signaling. Mol Biol Cell. 2005;16(6):2972-2983.
62. Pillozzi S, Brizzi MF, Bernabei PA, etal. VEGFR-1 (FLT-1), beta1integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood. 2007;110(4):1238-1250.